Facile Preparation of Calcium Phosphate Nanoparticles for Noninvasive Cancer Diagnosis
Peng Mi,Daisuke Kokuryo,Horacio Cabral,Michiaki Kumagai,Ichio Aoki,Nobuhiro Nishiyama,Kazunori Kataoka
2013-01-01
Abstract:SUMMARY Contrast agent doped, block copolymers hybrid calcium phosphate nanoparticles (CaP) were designed and developed for noninvasive diagnosis of solid tumors. A clinically used magnetic resonance imaging (MRI) contrast agent, diethylenetriaminepentaacetic acid gadolinium (III) (Gd-DTPA) was incorporated in the core of CaP by precipitating poly(ethylene glycol)-bpoly(aspartic acid) (PEG-b-PAsp) copolymer with calcium phosphate, and followed with hydrothermal synthetic procedures. Monodisperse, sub-100 nm of hybrid CaP nanoparticles (Gd-DTPA/CaP) with neutral surface ξ-potential were prepared and characterized. Besides, Gd-DTPA/CaP showed high colloidal stability in physiological environments, which contributed to long circulation in the bloodstream and high accumulation in solid tumors. Moreover, Gd-DTPA/CaP exhibited higher r1 relaxivity, and selective and sensitively enhanced the contrast of solid tumors. INTRODUCTION Precise detection of cancer is very important for clinical treatments. MRI provides a powerful, noninvasive way for tumor diagnosis with high spatial resolution and high quality of images. But it is often limited for cancer diagnosis by inadequate sensitivity, specificity and spatial resolution of contrast enhancement based on current clinically used low molecular paramagnetic contrast agents. Because of their fast clearance property from bloodstream and low-tissue specificity. Therefore, development of high sensitive and tumor specific MRI probes has become a big obstacle yet advocated much interests for cancer diagnosis. In those decades, many kinds of nanoparticles were developed to deliver small molecular drugs to specific organs for cancer diagnosis or chemotherapy. Recently, we developed a facile two-step method to prepare organic-inorganic hybrid nanoparticles. The nanoparticles stably incorporate Gd-DTPA (GdDTPA/CaP) with enhanced relaxivity and physiological stability for noninvasive in vivo cancer diagnosis by MRI as shown in Figure 1. Accordingly, spherical, monodisperse Gd-DTPA/CaP were firstly synthesized from a fast homogenous precipitation procedure using PEG-b-PAsp to control the hydroxyapatite crystal line growth as well as the size of nanoparticles. Then, GdDTPA/CaP were treated with a low temperature hydrothermal synthetic process to increase the colloidal stability. Becuase hydrothermal treatment is usually used to treat hydroxyapatite materials for orthopedics applications to enhance its mechanical reliability in wet environments. Gd-DTPA/CaP were evaluated with in vitro and in vivo experiments, and further applied for in vivo MRI contrast enhancement of solid tumors. Figure 1. Scheme illustrating the preparation of GdDTPA/CaP and characterized by TEM. EXPERIMENTAL METHODS PEG-b-poly (β-benzyl-L-aspartate) (PEG-b-PBLA) which was synthesized according to the previously described synthetic methods with minor changes. PEGb-PAsp block copolymer with 40 degree of polymerization (DP) was obtained from PEG-b-PBLA by de-protecting with sodium hydroxide. Gd-DTPA loaded Gd-DTPA/CaP was prepared by mixing Gd-DTPA, PEGb-PAsp, Ca and HPO4 in buffer. Then it was treated by hydrothermal synthesis at 120 °C for 20 min in Autoclave machine to increase the stability of the nanoparticles in wet environments. The obtained Gd-DTPA/CaP were characterized by a series of in vitro and in vivo experiments to study the morphology, colloidal stability, cytotoxicity, bioavailability, tumor accumulation and r1 relaxivity. All of the animal experiments were carried out following the policies of the Animal Ethics Committee of the University of Tokyo. Female BALB/c nude mice at the age of 6 weeks were purchased from Charles River Laboratories, Inc. (Tokyo, Japan). Murine colon adenocarcinoma 26 (C-26) cells were inoculated subcutaneously to mice for preparing tumor models for testing blood circulation time and tumor accumulation ability until the mean tumor volume was 100 mm. In vivo MR imaging of the tumors was conducted with a 1T imaging spectrometer (Aspect, Aspect Imaging) with the administration of Gd-DTPA/CaP nanoparticles as contrast agent. RESULTS AND DISCUSSION The harvested Gd-DTPA/CaP has a diameter of 80 nm and a ξ-potential value around -0.5 mV. GdDTPA/CaP has increased relaxivity of Gd-DTPA, which is about 18 mM S and this value is nearly 6 times higher than free Gd-DTPA. We also evaluated in vitro toxicity of Gd-DTPA/CaP against normal cell line (HUVEC cell) and cancer cell line (C-26 cell), and both results proved Gd-DTPA/CaP has low toxicity. In physiological conditions, Gd-DTPA/CaP exhibited high colloidal stability properties. Figure 2. Pharmacokinetic profile results of Gd-DTPA/ CaP in plasma (A) and solid tumor (B). Besides, we measured the amounts of Gd-DTPA delivered by Gd-DTPA/CaP in plasma and in subcutaneous C-26 tumors, and then compared the results with those after administration of free Gd-DTPA. Thus, free Gd-DTPA was rapidly cleared from plasma, and only trace amounts (nearly 0.001% dose/ml) were found in plasma 1 h after intravenous administration (Figure 2A). Accordingly, Gd-DTPA is a small molecular compound, which could be easily excreted from blood circulation, and it has been reported that only 10% of injected GdDTPA remains in blood after 5 min of administration in rats. Therefore, high doses or multi-injection of Gd (III) chelates is usually applied in clinical settings, but this may result in inaccuracies of diagnosis and potential toxicity. Indeed, free Gd-DTPA did not accumulate in the tumor tissue (Figure 2B). For Gd-DTPA/CaP, over 40% of Gd-DTPA was found in plasma 1 h after administration, and approximately 20% remained even 8 h later (Figure 2A), indicating that the blood circulation time of Gd-DTPA was remarkably extended by incorporation into CaP nanoparticles. Despite their prolonged blood circulation, safe Gd-DTPA released from Gd-DTPA/CaP can be cleared by kidney excretion, thus, less than 2% of Gd-DTPA was detected 24 h after injection, reducing the risks from extended exposure of Gd (III) compounds. Gd-DTPA/CaP gradually accumulated in tumor site after intravenous injection, to reach nearly 5% of the injected dose per gram tissue after 4 h (Figure 2B). The accumulation profile can be explained by the EPR effect observed for macromolecular drug carriers. Finally, Gd-DTPA/CaP and Gd-DTPA were used to enhance the MR contrast of C26 subcutaneous tumors in vivo (Figure 3A and B). After iv injection of GdDTPA/CaP, the contrast of the tumor site was gradually enhanced, but in case of Gd-DTPA, no contrast enhancements was investigated. The higher contrast of tumor site by Gd-DTPA/CaP might result from both the promoted accumulation of Gd-DTPA and the increased molecular relaxivity of Gd-DTPA/CaP. In contrast, no signal enhancement was observed for free Gd-DTPA even administrated with 4 times higher dose. These results demonstrated that MRI contrast enhancing ability of GdDTPA was greatly improved by incorporation into CaP nanoparticles. Figure 3. In vivo MRI results of C-26 subcutaneous tumor models bearing mice contrasted by Gd-DTPA/CaP and Gd-DTPA. (A) MRI images contrast enhanced by GdDTPA/CaP. (B) MRI images with administration of GdDTPA. CONCLUSION Gd-DTPA/CaP with unique colloidal stability and magnetic properties were synthesized by following a facile two-step synthetic approach, and used for MRI contrast enhancement of solid tumors. PEG-polyanion block copolymers effectively controlled the crystal growth of hydroxyapatite as well as the size of nanoparticles and, sub-100 nm, monodisperse GdDTPA/CaP were obtained. Gd-DTPA/CaP exhibited low cytotoxicity, high bioavailability and tumor specific target ability. Gd-DTPA/CaP had increased r1 relaxivity of GdDTPA, and positively enhanced the contrast of solid tumor for diagnosis by MRI. REFERENCES [1] R. Weissleder, et al. Nature, 452 (2008): 580-589. [2] K. Kataoka et al. Adv Drug Deliver Rev, 47 (2001): 113-131. [3] M.Z. Zhang, et al. Nano Today, 4 (2009): 508-517. [4] P. Mi et al. Biomaterials 34 (2013): 492-500. ACKNOWLEDGMENTS This work was supported in part by Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) from Japan Society for the Promotion of Science (JSPS).